UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for small cell lung cancer (SCLC) in the United Kingdom. Explore treatment pathways including immunotherapy and novel agents.
SCLC accounts for ~15% of lung cancers, affecting ~7,000 people per year in the UK. It grows and spreads faster than non-small cell lung cancer but initially responds well to chemotherapy and radiotherapy. It is strongly linked to smoking. About two-thirds of patients have extensive stage (spread beyond one lung) at diagnosis.
Limited stage: concurrent chemoradiation (cisplatin + etoposide) with consolidative radiotherapy. Prophylactic cranial irradiation (PCI) may be offered to reduce brain metastases. Extensive stage: chemotherapy (cisplatin or carboplatin + etoposide) + immunotherapy (atezolizumab or durvalumab). Second-line: lurbinectedin (recently approved), topotecan, or tarlatamab (bispecific antibody targeting DLL3 - showing impressive results).
Active UK SCLC trials include: bispecific antibodies (tarlatamab, BI 764532 targeting DLL3), ADCs targeting DLL3, new immunotherapy combinations, PARP inhibitors, and cancer vaccines. The aggressive nature of SCLC means clinical trials are particularly important for improving outcomes.
Free AI-powered matching - no signup required
Search SCLC Trials →